CORT
A courtroom cliffhanger
Corcept Therapeutics is back in the news, and not for the kind of reason management puts on a slide deck with confetti. The company is facing a securities fraud class action, and investors who bought stock during the class period have until April 21, 2026 to step up as lead plaintiff.
Why this matters
The lawsuit centers on Corcept’s December 31, 2025 FDA disappointment, when regulators issued a Complete Response Letter and declined to approve relacorilant for hypercortisolism. In plain English: the drug got sent back to the lab with a big fat “not yet.”
For investors, this is more than legal noise. A lawsuit like this can mean:
- ongoing headline risk
- more legal expenses
- pressure on sentiment while the case works its way through the system
The stock market hates uncertainty
Even when a company thinks it’s in the right, securities litigation can hang around like that one group chat you forgot to mute. Traders tend to dislike unresolved regulatory and legal messes, especially when the underlying issue is a key drug that was supposed to help drive future growth.
Big picture
This isn’t a fresh scientific readout or a new FDA win. It’s the legal aftermath of one — and that means the market may keep treating Corcept like a story with at least one more chapter left.